Nectar Lifesciences Limited (NSE:NECLIFE)
India
· Delayed Price · Currency is INR 24.30
+1.54 (6.77%)
Apr 24, 2025, 12:31 PM IST
Nectar Lifesciences Revenue
Nectar Lifesciences had revenue of 4.54B INR in the quarter ending December 31, 2024, with 0.48% growth. This brings the company's revenue in the last twelve months to 16.81B, up 3.02% year-over-year. In the fiscal year ending March 31, 2024, Nectar Lifesciences had annual revenue of 16.85B with 10.56% growth.
Revenue (ttm)
16.81B
Revenue Growth
+3.02%
P/S Ratio
0.30
Revenue / Employee
9.97M
Employees
1,686
Market Cap
5.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 16.85B | 1.61B | 10.56% |
| Mar 31, 2023 | 15.24B | -1.45B | -8.70% |
| Mar 31, 2022 | 16.69B | 1.26B | 8.13% |
| Mar 31, 2021 | 15.43B | -8.23B | -34.78% |
| Mar 31, 2020 | 23.66B | -4.16B | -14.97% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Nectar Lifesciences News
- 6 weeks ago - Nectar Lifesciences shares hit 5% lower circuit, down 10% in two days amid EU regulatory concerns - Business Upturn
- 2 months ago - Nectar Lifesciences shares surge nearly 5% as Q3 profit jumps 400% YoY - Business Upturn
- 2 months ago - Nectar Lifesciences Q3 FY25 results: Profit after tax rises nearly 400% YoY to Rs 7.84 crore - Business Upturn